サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1756396

レンチウイルスベクターの世界市場：製品種類別・治療領域別・製造規模別・ワークフロー段階別・用途別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Lentiviral Vectors Market, By Product Type, By Therapeutic Area, By Manufacturing Scale, By Workflow Stage, By Application, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 298 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.58円
レンチウイルスベクターの世界市場：製品種類別・治療領域別・製造規模別・ワークフロー段階別・用途別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年05月04日
発行: AnalystView Market Insights
ページ情報: 英文 298 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

レンチウイルスベクターの市場規模は2024年に1億7,010万米ドルとなり、2025年から2032年にかけてCAGR 11.92%で拡大

レンチウイルスベクターの市場力学

遺伝子導入システムの進歩がレンチウイルスベクターの採用を加速

遺伝子導入システムの進歩により、世界中の治療・研究用途でレンチウイルスベクターの採用が加速しています。米国国立がん研究所（NCI）の報告によると、レンチウイルスベクターはCAR-T細胞療法の要となっており、FDAが承認したいくつかの治療法では、標的がん治療のために患者の免疫細胞を改変するためにこれらのベクターを利用しています。さらに、米国国立衛生研究所（NIH）は、レンチウイルスベクターの安全性と拡張性を改善することを目的とした複数のプログラムに資金を提供し、挿入型変異誘発に関する懸念に対処しています。欧州では、EMAのような規制機関がレンチウイルスを用いた遺伝子治療の臨床試験承認を促進しており、これはその可能性に対する信頼の高まりを反映しています。こうした努力は、個別化医療の範囲を拡大し、遺伝性疾患や後天性疾患の治療選択肢を前進させる上で、遺伝子導入技術の強化が重要な役割を果たすことを強調しています。

レンチウイルスベクター市場：主な考察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2025-2032年）に約11.92%のCAGRで毎年成長すると推定されています。

製品タイプ別では、レンチウイルスパッケージングシステムが2024年に最大の市場シェアを示すと予測されています。

治療領域別では、がんが2024年の主要治療領域でした。

製造規模別では、2024年には臨床グレードが主要な製造規模となっています。

ワークフロー段階別では、2024年にはウイルスパッケージングがリードしています。

用途別では、細胞療法（CAR-Tなど）が2024年の主要用途でした。

地域別では、北米が2024年の主要収益源でした。

レンチウイルスベクター市場：セグメンテーション分析

レンチウイルスベクターの世界市場は、製品種類、治療領域、製造規模、ワークフロー段階、用途、地域に基づいてセグメント化されます。

市場は製品種類別に6つのカテゴリーに分けられます。レンチウイルスパッケージングシステム、レンチウイルスプラスミド、カスタムレンチウイルス生産サービス、Ready-to-useレンチウイルス、レンチウイルスプロモーター、レンチウイルス融合タグです。レンチウイルスパッケージングシステムはベクターアセンブリーにおける役割により優位を占めています。レンチウイルスプラスミドは遺伝子クローニングに不可欠です。

市場は治療領域に基づいて4つのカテゴリーに分けられます。がん、希少疾患、感染症、神経疾患です。希少疾患は個別化遺伝子治療の恩恵を受け、神経疾患は遺伝子編集とベクターデリバリーの研究が進む新たなターゲットです。

レンチウイルスベクター市場：地域別分析

レンチウイルスベクター市場は地域差が大きく、北米は確立されたバイオ医薬品インフラ、遺伝子治療研究への旺盛な資金提供、FDAを中心とした規制環境のサポートによりリードしています。米国では、特にCAR-T細胞療法や希少遺伝性疾患において、レンチウイルスベクターを利用した臨床試験が数多く実施されています。ドイツ、英国、フランスなどの国々が遺伝子治療の技術革新に多額の投資を行っており、欧州医薬品庁の合理化された規制経路の恩恵を受けています。アジア太平洋は、中国、日本、韓国でバイオテクノロジーと細胞治療プログラムを推進する政府の取り組みが活発化していることから、急速に台頭してきています。これらの国々では、学術機関とバイオテクノロジー企業との共同開発が活発化しており、レンチウイルスベクターを用いた治療法の臨床開発と商業化が加速しています。一方、ラテンアメリカと中東は、地域の遺伝性疾患への対応とヘルスケアアクセスの改善に焦点を当て、パートナーシップとインフラ開発を通じて徐々に能力を拡大しています。

レンチウイルスベクター市場：競合情勢

レンチウイルスベクター市場の競合情勢は、既存バイオテクノロジー企業、新興新興企業、遺伝子導入技術の進歩に注力する学術研究機関の組み合わせによって形成されています。大手企業は、遺伝子導入効率を向上させ、挿入突然変異誘発リスクを低減するため、より安全で効率的なレンチウイルスベクタープラットフォームの開発に投資しています。バイオ医薬品企業と学術センターとの戦略的提携やライセンシング契約は一般的で、迅速な技術革新と臨床応用を可能にしています。企業はまた、臨床グレードのレンチウイルスベクターに対する需要の高まりに対応するため、製造能力を拡大し、拡張性と規制遵守を重視しています。さらに、自己不活性化ベクターや標的送達システムなど、治療効果を高めるための新規ベクター工学技術の開発努力によって競合は激化しています。知的財産の管理と独自技術の独占的権利の確保は、進化するこの分野で市場での地位を維持し、長期的な成長を促進するために引き続き重要です。

目次

第1章 レンチウイルスベクター市場の概要

  • 分析範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 レンチウイルスベクターの主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 レンチウイルスベクター市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 レンチウイルスベクター市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 レンチウイルスベクターの市場情勢

  • レンチウイルスベクターの市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 レンチウイルスベクター市場：製品種類別

  • 概要
    • セグメント別シェア分析：製品種類別
    • レンチウイルスパッケージングシステム
    • レンチウイルスプラスミド
    • カスタムレンチウイルス生産サービス
    • Ready-to-useレンチウイルス
    • レンチウイルスプロモーター
    • レンチウイルス融合タグ

第8章 レンチウイルスベクター市場：治療領域別

  • 概要
    • セグメント別シェア分析：治療領域別
    • がん
    • 希少疾患
    • 感染症
    • 神経疾患

第9章 レンチウイルスベクター市場：製造規模別

  • 概要
    • セグメント別シェア分析：製造規模別
    • 研究グレード
    • 臨床グレード
    • 実用グレード

第10章 レンチウイルスベクター市場：ワークフロー段階別

  • 概要
    • セグメント別シェア分析：ワークフロー段階別
    • プラスミド構築
    • ウイルスパッケージング
    • 精製・濃縮
    • QC・分析
    • 上流工程処理
    • 下流工程処理

第11章 レンチウイルスベクター市場：用途別

  • 概要
    • セグメント別シェア分析：用途別
    • 遺伝子治療
    • 細胞療法（例：CAR-T）
    • ワクチン開発
    • 機能ゲノミクス

第12章 レンチウイルスベクター市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析：レンチウイルスベクター業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • Aldevron
    • Bio-Techne
    • Cell and Gene Therapy Catapult
    • Charles River Laboratories
    • Creative Biogene
    • ExcellGene SA
    • GeneCopoeia
    • Merck KGaA
    • OriGene Technologies
    • Oxford Biomedica
    • Sartorius AG
    • SIRION Biotech
    • Thermo Fisher Scientific
    • VectorBuilder
    • Vigene Biosciences
    • Wuxi Advanced Therapies
    • Others

第14章 AnalystViewの全方位的分析

目次
Product Code: ANV5351

REPORT HIGHLIGHT

Lentiviral Vectors Market size was valued at US$ 170.10 Million in 2024, expanding at a CAGR of 11.92% from 2025 to 2032.

The Lentiviral Vectors Market involves the development and use of lentivirus-based delivery systems primarily for gene therapy, vaccine development, and research applications. Increasing demand for effective gene delivery methods in treating genetic disorders and cancers has expanded the use of lentiviral vectors, which are favored for their ability to integrate into host genomes and provide stable, long-term gene expression. In 2023, over 60% of gene therapy clinical trials incorporated lentiviral vectors to enhance therapeutic outcomes. However, challenges like high manufacturing costs, biosafety concerns, and potential insertional mutagenesis limit widespread adoption. Advances in vector engineering and scalable production methods offer promising opportunities to improve safety profiles and reduce costs. Additionally, growing investments in CAR-T cell therapies and immunotherapy research present significant avenues for market expansion as lentiviral vectors play a crucial role in modifying immune cells for targeted treatments.

Lentiviral Vectors Market- Market Dynamics

Advancements in gene delivery systems to accelerate lentiviral vector adoption

Advancements in gene delivery systems are accelerating the adoption of lentiviral vectors in therapeutic and research applications worldwide. The National Cancer Institute (NCI) reports that lentiviral vectors have become a cornerstone in CAR-T cell therapies, with several FDA-approved treatments utilizing these vectors to modify patients' immune cells for targeted cancer treatment. Additionally, the U.S. National Institutes of Health (NIH) has funded multiple programs aimed at improving lentiviral vector safety and scalability, addressing concerns related to insertional mutagenesis. In Europe, regulatory agencies such as the EMA have facilitated clinical trial approvals for lentiviral-based gene therapies, reflecting growing confidence in their potential. These efforts underscore the critical role of enhanced gene delivery technologies in expanding the reach of personalized medicine and advancing treatment options for genetic and acquired diseases.

Lentiviral Vectors Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.92% over the forecast period (2025-2032)

Based on product type segmentation, Lentiviral Packaging Systems was predicted to show maximum market share in the year 2024

Based on Therapeutic Area segmentation, Cancer was the leading Therapeutic Area in 2024

Based on Manufacturing Scale segmentation, Clinical Grade was the leading Manufacturing Scale in 2024

Based on Workflow Stage segmentation, Viral Packaging was the leading Workflow Stage in 2024

Based on Application segmentation, Cell Therapy (e.g., CAR-T) was the leading Application in 2024

On the basis of region, North America was the leading revenue generator in 2024

Lentiviral Vectors Market- Segmentation Analysis:

The Global Lentiviral Vectors Market is segmented on the basis of Product Type, Therapeutic Area, Manufacturing Scale, Workflow Stage, Application, and Region.

The market is divided into six categories based on product type: Lentiviral Packaging Systems, Lentiviral Plasmids, Custom Lentivirus Production Services, Ready-to-use Lentivirus, Lentiviral Promoter, and Lentiviral Fusion Tags. Lentiviral Packaging Systems dominate due to their role in vector assembly; Lentiviral Plasmids are essential for gene cloning; Custom Lentivirus Production Services offer tailored solutions; Ready-to-use Lentivirus provides convenience; Lentiviral Promoters and Fusion Tags support gene expression and protein tracking.

The market is divided into four categories based on Therapeutic Area: Cancer, Rare Diseases, Infectious Diseases, and Neurological Disorders. Cancer leads as the primary therapeutic area due to extensive CAR-T applications; Rare Diseases benefit from personalized gene therapies; Infectious Diseases see growing vector use for vaccine development; Neurological Disorders are emerging targets with increasing research in gene editing and vector delivery.

Lentiviral Vectors Market- Geographical Insights

The Lentiviral Vectors Market shows significant regional variation, with North America leading due to its well-established biopharmaceutical infrastructure, robust funding for gene therapy research, and supportive regulatory environment led by the FDA. The U.S. hosts numerous clinical trials utilizing lentiviral vectors, particularly in CAR-T cell therapies and rare genetic disorders. Europe is also a key player, with countries like Germany, the UK, and France investing heavily in gene therapy innovation and benefiting from the European Medicines Agency's streamlined regulatory pathways. The Asia-Pacific region is rapidly emerging, driven by increased government initiatives in China, Japan, and South Korea to advance biotechnology and cell therapy programs. Growing collaborations between academic institutions and biotech firms in these countries are accelerating clinical development and commercialization of lentiviral vector-based therapies. Meanwhile, Latin America and the Middle East are gradually expanding their capabilities through partnerships and infrastructure development, focusing on addressing regional genetic disorders and improving healthcare access.

Lentiviral Vectors Market- Competitive Landscape:

The competitive landscape of the Lentiviral Vectors Market is shaped by a combination of established biotechnology companies, emerging startups, and academic research institutions focused on advancing gene delivery technologies. Leading players are investing in the development of safer, more efficient lentiviral vector platforms to improve transduction efficiency and reduce insertional mutagenesis risks. Strategic collaborations and licensing agreements between biopharma companies and academic centers are common, enabling rapid innovation and clinical translation. Companies are also expanding manufacturing capabilities to meet growing demand for clinical-grade lentiviral vectors, emphasizing scalability and regulatory compliance. Additionally, competition is intensified by efforts to develop novel vector engineering techniques, such as self-inactivating vectors and targeted delivery systems, to enhance therapeutic efficacy. Intellectual property management and securing exclusive rights to proprietary technologies remain critical for maintaining market position and fostering long-term growth in this evolving sector.

Recent Developments:

In June 2024, Charles River Laboratories announced a strategic collaboration with the Gates Institute at University of Colorado Anschutz to manufacture lentiviral vectors, accelerating CAR-T cell therapy development for hematological cancers and enhancing advanced cell and gene therapy manufacturing capabilities.

In September 2024, Rentschler Biopharma launched lentiviral vector manufacturing services at its Stevenage, UK facility, introducing a new LVV toolbox to complement existing AAV vector offerings and accelerate advanced therapy development for gene and cell therapy applications, including rare diseases and cancer immunotherapy.

In April 2025, ViroCell Biologics manufactured a GMP lentiviral vector for UCL's clinical trial, accelerating innovative CAR T-cell therapy development for relapsed paediatric acute lymphoblastic leukaemia, with the first patient enrolled in March 2025, aiming to prevent relapse in childhood blood cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LENTIVIRAL VECTORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Aldevron
  • Bio-Techne
  • Cell and Gene Therapy Catapult
  • Charles River Laboratories
  • Creative Biogene
  • ExcellGene SA
  • GeneCopoeia
  • Merck KGaA
  • OriGene Technologies
  • Oxford Biomedica
  • Sartorius AG
  • SIRION Biotech
  • Thermo Fisher Scientific
  • VectorBuilder
  • Vigene Biosciences
  • Wuxi Advanced Therapies
  • Others

GLOBAL LENTIVIRAL VECTORS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Lentiviral Packaging Systems
  • Lentiviral Plasmids
  • Custom Lentivirus Production Services
  • Ready-to-use Lentivirus
  • Lentiviral Promoter
  • Lentiviral Fusion Tags

GLOBAL LENTIVIRAL VECTORS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Cancer
  • Rare Diseases
  • Infectious Diseases
  • Neurological Disorders

GLOBAL LENTIVIRAL VECTORS MARKET, BY MANUFACTURING SCALE- MARKET ANALYSIS, 2019 - 2032

  • Research Grade
  • Clinical Grade
  • Commercial Grade

GLOBAL LENTIVIRAL VECTORS MARKET, BY WORKFLOW STAGE- MARKET ANALYSIS, 2019 - 2032

  • Plasmid Construction
  • Viral Packaging
  • Purification & Concentration
  • QC & Analytics
  • Upstream Processing
  • Downstream Processing

GLOBAL LENTIVIRAL VECTORS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Gene Therapy
  • Cell Therapy (e.g., CAR-T)
  • Vaccine Development
  • Functional Genomics

GLOBAL LENTIVIRAL VECTORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Lentiviral Vectors Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Lentiviral Vectors Market Snippet by Product Type
    • 2.1.2. Lentiviral Vectors Market Snippet by Therapeutic Area
    • 2.1.3. Lentiviral Vectors Market Snippet by Manufacturing Scale
    • 2.1.4. Lentiviral Vectors Market Snippet by Workflow Stage
    • 2.1.5. Lentiviral Vectors Market Snippet by Application
    • 2.1.6. Lentiviral Vectors Market Snippet by Country
    • 2.1.7. Lentiviral Vectors Market Snippet by Region
  • 2.2. Competitive Insights

3. Lentiviral Vectors Key Market Trends

  • 3.1. Lentiviral Vectors Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Lentiviral Vectors Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Lentiviral Vectors Market Opportunities
  • 3.4. Lentiviral Vectors Market Future Trends

4. Lentiviral Vectors Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Lentiviral Vectors Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Lentiviral Vectors Market Landscape

  • 6.1. Lentiviral Vectors Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Lentiviral Vectors Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Lentiviral Packaging Systems
    • 7.1.3. Lentiviral Plasmids
    • 7.1.4. Custom Lentivirus Production Services
    • 7.1.5. Ready-to-use Lentivirus
    • 7.1.6. Lentiviral Promoter
    • 7.1.7. Lentiviral Fusion Tags

8. Lentiviral Vectors Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 8.1.2. Cancer
    • 8.1.3. Rare Diseases
    • 8.1.4. Infectious Diseases
    • 8.1.5. Neurological Disorders

9. Lentiviral Vectors Market - By Manufacturing Scale

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Manufacturing Scale, 2024 & 2032 (%)
    • 9.1.2. Research Grade
    • 9.1.3. Clinical Grade
    • 9.1.4. Commercial Grade

10. Lentiviral Vectors Market - By Workflow Stage

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Workflow Stage, 2024 & 2032 (%)
    • 10.1.2. Plasmid Construction
    • 10.1.3. Viral Packaging
    • 10.1.4. Purification & Concentration
    • 10.1.5. QC & Analytics
    • 10.1.6. Upstream Processing
    • 10.1.7. Downstream Processing

11. Lentiviral Vectors Market - By Application

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 11.1.2. Gene Therapy
    • 11.1.3. Cell Therapy (e.g., CAR-T)
    • 11.1.4. Vaccine Development
    • 11.1.5. Functional Genomics

12. Lentiviral Vectors Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Lentiviral Vectors Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Lentiviral Vectors Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Lentiviral Vectors Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Lentiviral Vectors Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Lentiviral Vectors Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Manufacturing Scale, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Lentiviral Vectors Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Aldevron
    • 13.2.2. Bio-Techne
    • 13.2.3. Cell and Gene Therapy Catapult
    • 13.2.4. Charles River Laboratories
    • 13.2.5. Creative Biogene
    • 13.2.6. ExcellGene SA
    • 13.2.7. GeneCopoeia
    • 13.2.8. Merck KGaA
    • 13.2.9. OriGene Technologies
    • 13.2.10. Oxford Biomedica
    • 13.2.11. Sartorius AG
    • 13.2.12. SIRION Biotech
    • 13.2.13. Thermo Fisher Scientific
    • 13.2.14. VectorBuilder
    • 13.2.15. Vigene Biosciences
    • 13.2.16. Wuxi Advanced Therapies
    • 13.2.17. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us